Belvedere Trading
OCUL icon

Belvedere Trading’s Ocular Therapeutix OCUL Stock Holding History

Belvedere Trading’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,257
Closed -$3.95K – 940
2023
Q3 		$3.95K Buy
+1,257
New +$5.14K ﹤0.01% 568
2021
Q3 		– Sell
-23,347
Closed -$289K – 553
2021
Q2 		$289K Buy
+23,347
New +$355K 0.02% 157

Other funds holding OCUL

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Belvedere Trading's OCUL Position: Q4 2023 in Review

Belvedere Trading sold out of Ocular Therapeutix (OCUL) in Q4 2023, closing a stake of 1,257 shares — an estimated $3.95K sold.

Belvedere Trading first reported a position in OCUL in Q2 2021 and held it in 2 quarters. The position peaked at $289K in Q2 2021. 118 funds tracked by Wall St. Rank hold OCUL as of Q4 2023.

  • Belvedere Trading reported no remaining Ocular Therapeutix position as of Q4 2023 after selling out during the quarter.
  • Belvedere Trading sold 1,257 Ocular Therapeutix shares in Q4 2023, an estimated $3.95K.
  • Belvedere Trading first reported a position in Ocular Therapeutix in Q2 2021 and held it in 2 quarters.
  • Belvedere Trading's Ocular Therapeutix position peaked at $289K in Q2 2021.
  • 118 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.